Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D/A 0001870044 XXXXXXXX LIVE 5 Ordinary Shares 06/10/2026 false 0001857190 B6S7WD106 Nyxoah SA Rue Edouard Belin, 12 Mont-Saint-Guibert C9 1435 Rob McGrory 61294255239 1 University Avenue Macquarie University C3 2109 Y Cochlear Investments Pty Ltd AF N C3 0.00 5847283.00 0.00 5847283.00 5847283.00 N 5.91 CO Based on 98,894,961 ordinary shares ("Ordinary Shares") of Nyxoah S.A. (the "Issuer") outstanding, as stated in the Issuer's prospectus supplement filed with the U.S. Securities and Exchange Commission (the "SEC") on June 5, 2026. 0001870044 N Cochlear Limited WC N C3 0.00 5847283.00 0.00 5847283.00 5847283.00 N 5.91 CO Based on 98,894,961 Ordinary Shares outstanding, as stated in the Issuer's prospectus supplement filed with the SEC on June 5, 2026. Ordinary Shares Nyxoah SA Rue Edouard Belin, 12 Mont-Saint-Guibert C9 1435 This Amendment No. 5 (this "Amendment") amends and supplements the Schedule 13D filed by the Reporting Persons on July 16, 2021 (the "Original Schedule 13D") as amended by Amendment No. 4 to the Original Schedule 13D filed by the Reporting Persons dated November 24, 2025 ("Amendment No. 4"), Amendment No. 3 to the Original Schedule 13D filed by the Reporting Persons dated October 10, 2024 ("Amendment No. 3"), Amendment No. 2 to the Original Schedule 13D filed by the Reporting Persons on May 30, 2024 ("Amendment No. 2") and Amendment No. 1 to the Original Schedule 13D filed by the Reporting Persons on March 29, 2023 (together with Amendment No. 4, Amendment No. 3, Amendment No. 2and the Original Schedule 13D, the "Schedule 13D"). Except as specifically provided herein, this Amendment does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used but not otherwise defined in this Amendment shall have the same meanings ascribed to them in the Schedule 13D. As of the date hereof, Cochlear Investments directly owns 5,847,283 Ordinary Shares, representing 5.91% of the outstanding Ordinary Shares. Cochlear Limited is the parent company of Cochlear Investments. As a result, Cochlear Limited may be deemed to indirectly beneficially own the Ordinary Shares directly held by Cochlear Investments. The percentage of outstanding Ordinary Shares that may be deemed to be beneficially owned by each Reporting Person is set forth on line 13 of the cover sheet hereof. Such percentage was calculated based on 98,894,961 Ordinary Shares outstanding, as stated in the Issuer's prospectus supplement filed with the SEC on June 5, 2026. The Reporting Persons do not have the right to acquire any additional Ordinary Shares. The reported share amounts for the Reporting Persons reflect amounts as of the date hereof. The Reporting Persons have not effected any transactions in the Ordinary Shares during the past 60 days. Cochlear Investments Pty Ltd /s/ Kristy Jo Kristy Jo / Company Secretary 06/11/2026 Cochlear Limited /s/ Rob McGrory Rob McGrory / Company Secretary 06/11/2026